Drug intelligence / Profile preview

CRB2110

Development stage: Preclinical
Lead developer: China Resources Pharmaceutical Holdings
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CRB2110 is a preclinical-stage bifunctional (bispecific) monoclonal antibody being developed by China Resources Angde Biopharmaceutical (a subsidiary of China Resources Biopharmaceutical) for the treatment of oncology. The drug candidate was designed and optimized using artificial intelligence (AI) and computer-aided drug design (CADD) platforms to achieve efficient and cost-effective molecular screening and design, specifically targeting complex structures and improving binding affinity.

Beyond the preview

Go deeper on CRB2110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRB2110.

Explore the full profile